A Randomized Multicenter Phase III Study Comparing Paclitaxel Plus Capecitabine Plus Capecitabine Maintenance Treatment Versus Cisplatin Plus Capecitabine in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction.

Trial Profile

A Randomized Multicenter Phase III Study Comparing Paclitaxel Plus Capecitabine Plus Capecitabine Maintenance Treatment Versus Cisplatin Plus Capecitabine in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 May 2017

At a glance

  • Drugs Capecitabine (Primary) ; Cisplatin; Paclitaxel
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 May 2015 Planned End Date changed from 1 Aug 2012 to 1 Aug 2015 as reported by ClinicalTrials.gov record.
    • 30 Jun 2012 Interim tolerability results presented at the 14th World Congress on Gastrointestinal Cancer.
    • 27 Sep 2011 Results presented at the 2011 European Multidisciplinary Cancer Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top